Good interview

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

The Straight Pipes (1.8M YouTube subs) reviewed the new @Tesla Model Y Performance, and they spent most of the time talking about how good FSD (Supervised) V14 is lol. "It slowed for a bird! The Full-Self Driving is unreal. Mind-blowing. I was driving it in the city on my normal routes, kid to daycare, where I grew up, this is insane. It's so good." Full review: youtube.com/watch?v=i7ELbXfz…

SpaceX

Personal update: I've joined Anthropic. I think the next few years at the frontier of LLMs will be especially formative. I am very excited to join the team here and get back to R&D. I remain deeply passionate about education and plan to resume my work on it in time.

True

Day 6 is live: Watch our humanoid robots running 24/7 and fully autonomous. We've now crossed 119 consecutive hours and 149,000 packages x.com/i/broadcasts/1kKzDMRBp…

The next great arbitrage opportunity will be differentiated humans in a world flooded with undifferentiated AI

Day 2 is Live: Watch humanoid robots Bob, Frank, and Gary running 24/7. This is fully autonomous running Helix-02 x.com/i/broadcasts/1AxRnakog…

Watch a team of humanoid robots running a full 8-hr shift at human performance levels. This is fully autonomous running Helix-02 x.com/i/broadcasts/1dxYljYVR…

Figure taught two robots to make a bed together - fully autonomous Honestly, they’re better at it than most humans

YUGE! ALSO: 31 unsupervised Robotaxis now. At this rate, we will hit 1800 in May lol

Today, we’re launching the @link wallet for agents. It lets you securely empower agents to spend on your behalf. Your payment credentials are never exposed and you approve every purchase. link.com/agents

Elon Musk explains his 5-step algorithm for solving any problem: "The most common mistake of smart engineers is to optimize a thing that should not exist." "I have this very basic first principles algorithm that I run as a mantra." Elon breaks it down: Step 1: Question the requirements. "Make the requirements less dumb. The requirements are always dumb to some degree, no matter how smart the person who gave you those requirements. You have to start there, because otherwise you could get the perfect answer to the wrong question." Step 2: Try to delete it. "Try to delete the part or the process step entirely. If you're not forced to put back at least 10% of what you delete, you're not deleting enough. Most people feel like they've succeeded if they haven't been forced to put things back in. But actually they haven't, they've been overly conservative and left things in that shouldn't be there." Step 3: Optimize or simplify. "The most common mistake of smart engineers is to optimize a thing that should not exist. So you don't optimize until after you've tried to delete." Step 4: Speed it up. "Any given thing can be done faster than you think. But you shouldn't speed things up until you've tried to delete it and optimize it otherwise, you're speeding up something that shouldn't exist." Step 5: Automate. "And then the fifth thing is to automate it." Elon explains why the order matters: "I've gone backwards so many times where I've automated something, sped it up, simplified it, and then deleted it. I got tired of doing that. So that's why I have this mantra."

The first behind the scenes of Figure’s new campus

Apple will do to smart glasses what they did to smartphones, arrive late and own the platform. LLM-agnostic spatial computing is the play that everyone builds on.

The Tesla "T" logo comes from Nikola Tesla's original electric motor patent btw Pretty cool.

Uber driver picked us up in a Tesla and I immediately asked him if he had Autopilot. He said yes and asked if we were comfortable with him using it for the ride. Of course we all said yes A red light we were stopped at turned green but the Tesla didn’t move. A second later a car blew through the red light from the opposite direction. The Tesla saved us from potentially being T-boned and getting into a really bad accident. Honestly driving with autopilot is crazy safe. I feel so comfortable with the Tesla driving compared to a stranger.

In 10 years from now, how many people do you think will have $meta glasses? Major push for these smart ai glasses right now. The numbers are showing they are catching on. 2024: 1 million units sold 2025: 2 million units sold since Oct 2023 debut. Q2 of 2025 sales tripled. Meta’s production goal = 10 million glasses produced by EOY 2026